Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis

• DOI: 10.1111/hepr.13243
• Publication Date: 2018-08-24T16:29:17Z
• Authors: Atsushi Hiraoka; Takashi Kumada; Kazuya Kariyama; Koichi Takaguchi; Ei Itobayashi; Noritomo Shimada; Kazuto Tajiri; Kunihiko Tsuji; Toru Ishikawa; Hironori Ochi; Masashi Hirooka; Akemi Tsutsui; Hiroshi Shibata; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Kouji Joko; Yoichi Hiasa; Kojiro Michitaka
• Keywords: Lenvatinib; Regorafenib

Lenvatinib (LEN) has recently become available as a first-line tyrosine-kinase inhibitor (TKI) for unresectable hepatocellular carcinoma (u-HCC). In patients who showed intolerability or failure in other TKI treatments, alternative treatment options are needed. This retrospective study evaluated the therapeutic potential of LEN clinical practice.We enrolled 57 u-HCC treated with from March to June 2018. was given orally weighing <60 kg at 8 mg/day and 12 those ≥60 kg. Following exclusion whose initial dose reduced, 49 were regard their characteristics early response using modified Response Evaluation Criteria Solid Tumors findings follow-up computed tomography (CT)/magnetic resonance imaging (MRI) examinations 4 weeks after introducing LEN.The average patient age 72.4 ± 9.3 years 38 (77.6%) men. The mg 32 17 patients, respectively. Twenty-nine (59.2%) had history sorafenib six them (20.7%) regorafenib. Of 27 obtained by enhanced CT/MRI LEN. Partial shown 11, stable disease 12, progressive four (overall rate [ORR], 40.7%; control [DCR], 85.2%). ORR DCR TKI-naïve (n = 8) 50.0% 87.5%, respectively, whereas TKI-experienced 19) 36.8% 84.2%, respectively (P 0.675 P 1.00, respectively).Early favorable. new could have both without past treatments.